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In Brief
Aspartate is a limiting metabolite for
proliferation in cells with mitochondrial
electron transport chain defects.
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The mitochondrial electron transport chain (ETC) en-
ables many metabolic processes, but why its inhibi-
tion suppresses cell proliferation is unclear. It is
also not well understoodwhy pyruvate supplementa-
tion allows cells lacking ETC function to proliferate.
We used a CRISPR-based genetic screen to identify
genes whose loss sensitizes human cells to phenfor-
min, a complex I inhibitor. The screen yielded GOT1,
the cytosolic aspartate aminotransferase, loss of
which kills cells upon ETC inhibition. GOT1 normally
consumes aspartate to transfer electrons into mito-
chondria, but, upon ETC inhibition, it reverses to
generate aspartate in the cytosol, which partially
compensates for the loss of mitochondrial aspartate
synthesis. Pyruvate stimulates aspartate synthesis in
a GOT1-dependent fashion, which is required for
pyruvate to rescue proliferation of cells with ETC
dysfunction. Aspartate supplementation or overex-
pression of an aspartate transporter allows cells
without ETC activity to proliferate. Thus, enabling
aspartate synthesis is an essential role of the ETC
in cell proliferation.
INTRODUCTION
The mitochondrial electron transport chain (ETC) consists of four
enzyme complexes that transfer electrons from donors like
NADH to oxygen, the ultimate electron acceptor. During electron
transfer, the ETCpumps protons into the inter-membrane space,
generating a gradient across the inner mitochondrial membrane
that the FoF1 ATPase exploits to drive ATP synthesis (Mitchell,
1961; Nicholls and Budd, 2000; Wallace, 2013). Many metabolic
pathways, including glycolysis, the TCA cycle, and beta-oxida-
tion, produce the electron donors that fuel the ETC. In turn,
ETC activity impacts a variety of processes beyond energy bal-
ance (Pagliarini and Rutter, 2013), such as reactive oxygen spe-
cies (ROS) production (Bell et al., 2007; Boveris et al., 1972), the540 Cell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc.redox state (Di Lisa and Ziegler, 2001; Stein and Imai, 2012),
mitochondrial membrane potential (Chen et al., 2014), mitochon-
drial protein import (Geissler et al., 2000), apoptosis (Green and
Reed, 1998), and signaling (Chandel, 2014). Diseases caused by
genetic defects in the ETC are characterized by diverse pathol-
ogies (Koopman et al., 2012), like neurodegeneration (Bender
et al., 2006; Swerdlow et al., 1996), myopathy (DiMauro, 2010),
and deafness (Kokotas et al., 2007; Raimundo et al., 2012), but
in most cases it is unclear how ETC dysfunction leads to the spe-
cific symptom and sign.
One consequence of ETC dysfunction is impaired cell prolifer-
ation, and human cells in culture arrest upon pharmacological or
genetic inhibition of complex I (Fendt et al., 2013; Wheaton et al.,
2014) or III (Han et al., 2008; Howell and Sager, 1979). Even
thoughchanges inATPorROS levels havebeensuggested to un-
derlie the anti-proliferative effects of ETC inhibition (Wallace,
1999), the exact reason why proliferation requires the ETC is
not understood. Interestingly, it has long been known that human
cells lacking a functional ETC can proliferate if cultured in supra-
physiological concentrationsof pyruvate (King andAttardi, 1989).
While pyruvate can serve as a biosynthetic substrate or affect the
redox state of the cell by promoting the regeneration of NAD+
(Harris, 1980; Howell and Sager, 1979), why it reverses the sup-
pressive effects of ETC inhibition on cell proliferation is unknown.
Here, through a CRISPR (clustered regularly interspaced short
palindromic repeat)-based genetic screen, we discovered that a
key function of the ETC required for cell proliferation is to enable
the synthesis of aspartate, a proteogenic amino acid that is also
a precursor in purine and pyrimidine synthesis (Lane and Fan,
2015). Aspartate becomes limiting upon ETC inhibition and its
supplementation, like that of pyruvate, allows cells with defective
ETC activity to proliferate. Finally, we find that pyruvate reverses
the anti-proliferative effects of ETC inhibition by inducing aspar-
tate synthesis.
RESULTS AND DISCUSSION
A CRISPR-Based Genetic Screen For Metabolic Genes
that When Lost Sensitize Human Cells to Phenformin
Pharmacological or genetic inhibition of the ETC greatly sup-
presses cell proliferation (Santidrian et al., 2013; Wheaton
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Figure 1. A CRISPR-Based Genetic Screen Identifies Metabolic Genes Whose Loss Sensitizes Human Cells to Phenformin
(A) Dose-dependent effects of phenformin on Jurkat cell proliferation (mean ± SD, n = 3).
(B) Schematic depicting the pooled CRISPR-based screen. PD, Population doublings.
(C) Gene scores in untreated versus phenformin-treated (0.5 mM) Jurkat cells. The gene score is the median log2 fold change in the abundance of all sgRNAs
targeting that gene during the culture period. Most genes, aswell as non-targeting control sgRNAs, have similar scores in the presence or absence of phenformin.
(D) Top 25 genes scoring as differentially required upon phenformin treatment (top). Genes linked to the GOT1-catalyzed transamination reaction are indicated in
red, the ETC in blue, and to nucleotide biosynthesis in green. The top-scoring gene, GOT1, catalyzes the transamination of aspartate to alpha-ketoglutarate
yielding L-glutamate and oxaloacetate (OAA) and requires PLP as a cofactor (bottom).
(E) Changes in abundance in the primary screen of the individual GOT1 sgRNAs in the presence (gray) or absence (black) of phenformin.
(F) GOT1-null cells die upon phenformin treatment. Immunoblot analysis for indicated proteins of wild-type and GOT1-null Jurkat cells (top). Akt was used as a
loading control. Fold change in cell number log2 of wild-type (black) andGOT1-null (blue) Jurkat cells after treatment with indicated phenformin concentrations for
5 days (mean ± SD, n = 3) (bottom). Representative bright-field micrographs of indicated cells after a 5-day phenformin treatment (right).
(G) Expression of an sgRNA-resistant GOT1 cDNA rescues phenformin sensitivity of the GOT1-null Jurkat cells. Immunoblot analysis of wild-type, GOT1-null, and
rescued null cells (top). Raptor was used as a loading control. Fold change in cell number log2 of wild-type (black), GOT1-null (blue), and rescued GOT1-null (gray)
cells after a 5-day treatment with indicated phenformin concentrations (mean ± SD, for n = 3) (bottom).et al., 2014) (Figure 1A), but exactly why is unclear. To study
this question, we performed a CRISPR-based negative selec-
tion screen for genes whose loss potentiates the anti-prolifera-
tive effects of mild ETC inhibition. Such genes should reveal
processes that help cells adapt to ETC impairment and thus
pinpoint key ETC functions in proliferating cells. Given the
central role of mitochondria in metabolism, we generated a
library consisting of 30,000 sgRNAs targeting 3,000 meta-bolic enzymes, small molecule transporters, and metabolism-
related transcription factors (10 sgRNA/gene) as well as 500
control sgRNAs in a Cas9-expressing lentiviral vector (Fig-
ure 1B). We transduced human Jurkat leukemic T cells with
the sgRNA library, and passaged the pool of knockout cells
in pyruvate-free RPMI media for 14 population doublings in
the presence or absence of 0.5 mM phenformin. This lipophilic
biguanide inhibits complex I of the ETC (Birsoy et al., 2014;Cell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc. 541
Owen et al., 2000; Wheaton et al., 2014) and only mildly
slowed proliferation at the concentration used (Figure 1A). As
expected for an ETC inhibitor, phenformin dose-dependently
suppressed respiration as measured by oxygen consumption
(Figure S1D).
Using massively parallel sequencing, we measured the abun-
dances of all the sgRNAs in the vehicle- and phenformin-treated
Jurkat cells at the beginning and at the end of the culture period.
For each gene, we calculated its score as the median log2 fold
change in the abundance of the 10 sgRNAs targeting the
gene. As expected, most genes, as well as the control sgRNAs,
scored similarly in the presence or absence of phenformin
(Figure 1C).
Among the genes selectively required in the presence of
phenformin, were several encoding ETC-related proteins,
including complex I subunits (NDUFA11, NDUFB2, NDUFA10,
NDUFB9), mitochondrial RNA processing and ubiquinone syn-
thesis enzymes (PDE12 and COQ4), and ETC assembly factors
(ACAD9 and SCO2) (Figure 1D, Figure S1B). Unlike genes en-
coding core ETC components, these genes were not essential
in the absence of phenformin (Figure S1A). This suggests that
they are not absolutely required for ETC function, explaining
why their loss synergize with low-dose phenformin. These
results are consistent with the previous finding that cells having
heteroplasmic mitochondrial DNA mutations that partially
impair the ETC are hypersensitive to phenformin (Birsoy
et al., 2014).
The best scoring gene in the screen was GOT1, which
encodes the cytosolic aspartate aminotransferase that is part
of the malate-aspartate shuttle for transferring reducing equiva-
lents to the mitochondrial matrix (Figures 1D and 1E). GOT1
catalyzes the reversible transfer of an amino group between
aspartate and glutamate, and like other transaminases, requires
pyridoxal-5-phosphate (PLP) as a cofactor (Toney, 2014) (Fig-
ure 1D). Interestingly, the fourth highest scoring gene, PDXK,
encodes a pyridoxal kinase, which converts vitamin B6 to
PLP (Figure S1C). These data strongly suggest that a GOT1-
catalyzed reaction is important for maintaining cellular fitness
upon mild phenformin treatment. Given its high score and unex-
plored role during ETC inhibition, we focused our attention on
GOT1.
ETC Inhibition Kills Cells Lacking GOT1
To begin to understand how GOT1 loss sensitizes cells to phen-
formin, we used the CRISPR-Cas9 system to generate two
clonal Jurkat cell lines in which the GOT1 protein was undetect-
able (GOT1_KO1 and GOT1_KO2) (Figure 1F). Under normal cul-
ture conditions, GOT1-null cells are viable and proliferate at
slightly slower rates than wild-type cells (Figure S1E). Consistent
with the results of the screen, low doses of phenformin inhibited
the proliferation of GOT1-null cells to a much greater extent than
that of wild-type cells (Figure 1F). Remarkably, at the higher con-
centrations of phenformin that strongly repress respiration (Fig-
ure S1D), GOT1-null cells arrested and died, while the wild-
type counterparts did not (Figure 1F, Figure S1E). Importantly,
expression of an sgGOT1-resistant human GOT1 cDNA in the
null cells eliminated their hypersensitivity to phenformin (Fig-
ure 1G). These findings validate the screening results and reveal542 Cell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc.that GOT1 loss and phenformin interact synergistically in Jurkat
cells.
To ask if GOT1 loss sensitizes other cell types to ETC inhibi-
tion, we knocked out GOT1 in human Raji lymphoma and
KMS-26 multiple myeloma cells, as well as immortalized mouse
embryonic fibroblasts (MEFs) (Figure 2A, Figure S2A). Indeed,
all the GOT1-null cells were far more sensitive to phenformin
than their wild-type counterparts, indicating a generalizable
role for GOT1 in cells treated with phenformin (Figure 2A,
Figure S2A).
Finally, inhibition of different complexes of the ETC can have
pleiotropic effects on metabolism (Bell et al., 2007; Frezza
et al., 2011). This raised the possibility that the sensitizing effect
of GOT1 loss might be specific to complex I inhibition or even
phenformin treatment, in particular. However, this is not the
case because compared to wild-type cells, those lacking
GOT1 were substantially more sensitive to other complex I
inhibitors (metformin and piericidin) as well as the complex III
inhibitor, antimycin (Figure 2B, Figures S2B and S2C). These
data indicate that GOT1 loss has a synthetic lethal interaction
with ETC dysfunction, independently of which complex is
inhibited.
Upon ETC Inhibition GOT1 Reverses Flux and Generates
Aspartate
GOT1 is part of the malate-aspartate shuttle (Figure 3A, Fig-
ure S3A), but no other component of the shuttle (MDH1,
MDH2, SLC25A13, GOT2) scored in the screen (Figure S3B).
Given these results, we focused on the reaction mediated by
GOT1 itself rather than the overall function of the shuttle in trans-
ferring reducing equivalents into the mitochondrial matrix.
In normal cells, GOT1 is thought to use aspartate and alpha-
ketoglutarate to make oxaloacetate and glutamate (Safer,
1975). Consistent with GOT1 consuming aspartate, its levels
are 4- to 5-fold higher in GOT1-null than wild-type Jurkat cells
(Figure 3B) (Son et al., 2013). Aspartate is normally synthesized
in the mitochondrial matrix through the sequential actions
of MDH2 and GOT2 and then transported to the cytosol for
use by GOT1 and other enzymes (Figure 3A). Because MDH2
is an oxidoreductase, the drop in the NAD+/NADH ratio that
occurs upon ETC dysfunction should inhibit MDH2 and thus
mitochondrial aspartate synthesis. Indeed, in wild-type Jurkat
cells, phenformin caused aspartate levels to fall by 3-fold
(Figure 3B).
As GOT1 is bidirectional, the drop in aspartate levels might
allow GOT1 to reverse flux so that in cells with ETC dysfunction
GOT1 generates rather than consumes aspartate. If this were
the case, ETC inhibition should cause aspartate to drop to a
greater extent in GOT1-null than wild-type cells. Indeed, in
GOT1-null cells, phenformin treatment leads to an almost com-
plete loss of cellular aspartate (30-fold reduction) without
much effect on other amino acids (Figure 3B). Thus, upon
ETC inhibition, cells use a GOT1-dependent pathway to
generate aspartate. It is important to note, however, that this
pathway does not fully compensate for loss of mitochondrial
aspartate synthesis as aspartate is 3-fold lower in cells without
a functional ETC (Figure 3B). To understand if aspartate levels
also drop upon ETC inhibition in a differentiated cell in vivo, we
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Figure 2. ETC inhibition Kills Cells Lacking
GOT1
(A) GOT1 loss sensitizes various human cell types
to phenformin treatment. Immunoblot analysis of
wild-type and GOT1-null Raji and KMS-26 cells
(left). Raptor was used as a loading control. Fold
change in cell number log2 of wild-type (black) and
GOT1-null (blue) KMS-26 and Raji cells after a 5-
day treatment with indicated phenformin concen-
trations (mean ± SD, n = 3) (right).
(B) GOT1-null cells die upon ETC dysfunction
induced with various ETC inhibitors. Graphical
scheme depicting the targets of phenformin
(complex I inhibitor), piericidin (complex I inhibitor),
and antimycin (complex III inhibitor) (left). Fold
change in cell number log2 of wild-type (black),
GOT1-null (blue), and rescued GOT1-null (gray)
Jurkat cells after a 5-day treatment with indicated
piericidin and antimycin concentrations (mean ±
SD, n = 3) (right).generated a previously reported mouse strain with the heart-
specific deletion of mitochondrial transcription factor A (Tfam)
(Hansson et al., 2004). Consistent with the severe ETC defect
caused by Tfam loss, Tfam knockout hearts had a two-fold
lower ratio of aspartate to leucine than wild-type hearts
(Figure 3C).
Aspartate Supplementation Enables Cells to Proliferate
under Pharmacological ETC Inhibition
Because aspartate is required for the synthesis of proteins as
well as purines and pyrimidines (Lane and Fan, 2015), we
reasoned that the drop in aspartate levels caused by ETC inhibi-
tion might lead to the concomitant suppression of cell prolifera-
tion. Consistent with this notion, supplementation of RPMImedia
with aspartate (10 mM) partially reversed the anti-proliferative
effects of phenformin on wild-type cells (Figure 3D). Aspartate
addition also prevented the phenformin-induced death of
GOT1-null cells and even enabled these cells to proliferate in
the presence of the drug (Figure 3D). Given these findings, we
re-examined our screen hits and noted that several enzymes
scored that use aspartate for purine and pyrimidine synthesis
(Figure 1D, Figure S1B).
The aspartate rescue experiments required supplementation
of the media with concentrations of aspartate (10 mM) that are
higher than those found in standard media (Figure 3D), which
is likely a consequence of Jurkat cells having poor aspartate
transport. To test this possibility, we cultured GOT1-null cells
stably expressing the SLC1A3 glutamate-aspartate transporter
in standard RPMI, containing 150 mMaspartate. SLC1A3 imports
aspartate (Storck et al., 1992) and is highly expressed in neuronal
tissues but not in Jurkat cells (Figures S3C and S3D). Remark-
ably, SLC1A3 overexpression prevented the death of the
GOT1-null cells caused by phenformin (Figure 3E, Figure S3E)
and other ETC inhibitors (Figure S3F) and, like high dose aspar-
tate, enabled the proliferation of these cells (Figure 3D, Figures
S3E and S3F). Thus, we conclude that upon ETC inhibition,aspartate becomes limiting for maintaining the viability and pro-
liferation of cells.
Metabolic Route for Aspartate Synthesis in Cells with
ETC Inhibition
To generate aspartate in cells with ETC inhibition, GOT1 must
have a source of oxaloacetate (Figure S4A), which can be
made from (1) malate by the cytosolic (MDH1) or mitochondrial
(MDH2) malate dehydrogenases; (2) pyruvate by pyruvate
carboxylase (PC) in mitochondria; or (3) citrate by ATP-citrate
lyase (ACL) in the cytosol. MDH1, MDH2, or PC did not score
in our screen as differentially essential upon mild phenformin
treatment (Figure S3B, Figure S4B), so we focused on the
possible generation of oxaloacetate from citrate upon ETC inhi-
bition. In cells with ETC dysfunction, glutamine is a major
source of citrate through the ‘‘reductive carboxylation’’
pathway (Metallo et al., 2012; Mullen et al., 2012). In reductive
carboxylation, the mitochondrial citrate carrier (SLC25A1)
transports glutamine-derived citrate to the cytosol, where
ACL cleaves it into oxaloacetate. Consistent with oxaloacetate
being generated from citrate in cells with ETC inhibition,
SLC25A1 scored as differentially required in our phenformin
screen (Figure 1D). The differential requirement of ACL could
not be assessed because it scored as essential under all con-
ditions (Figure S4B), likely because it is required for fatty acid
synthesis.
To directly determine how aspartate is made, wemeasured its
generation from [U-13C]-L-glutamine in wild-type and GOT1-null
Jurkat cells treated with or without phenformin. Oxidative meta-
bolism of the uniformly labeled glutamine will generate aspartate
with four 13C atoms (m+4), while aspartate made by reductive
carboxylation will have three 13C atoms (m+3) (Figure 4A). Under
normal conditions, we found that oxidative glutamine meta-
bolism was the predominant source of aspartate (50% of
total aspartate pool) in both wild-type and GOT1-null Jurkat
cells (Figure 4B). Upon ETC inhibition, aspartate synthesisCell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc. 543
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Figure 3. Upon ETC Inhibition, GOT1 Reverses and Generates Aspartate, Which Is Limiting for Cell Proliferation
(A) Schematic depicting the malate-aspartate shuttle. Normally, the malate-aspartate shuttle runs in the forward direction to transfer reducing equivalents across
the mitochondrial membrane. GOT1 is part of the malate-aspartate shuttle and consumes aspartate to generate oxaloacetate (OAA). Aspartate produced by
mitochondria is a precursor for protein and nucleotide biosynthesis.
(B) Upon ETC inhibition, GOT1 reverses and consumes aspartate. Relative abundance of indicated amino acids in wild-type and GOT1-null Jurkat cells after a
24 hr treatment in the presence (gray) or absence of (black) phenformin (mean ± SD, n = 3). All measurements are relative to untreated wild-type Jurkat cells.
(C) Tfam knockout hearts have a lower ratio of aspartate to leucine than wild-type hearts. Immunoblot analyses of TFAM and COXI in wild-type and TFAM-null
murine hearts (left). S6K1 was used as a loading control. Relative ratio of aspartate to leucine in wild-type and TFAM-null mouse hearts (mean ± SD, n = 7 (wild-
type) and n = 6 (TFAM-null), **p < 0.05).
(D) Aspartate supplementation rescues death of GOT1-null cells upon ETC inhibition. Fold change in cell number (log2) of wild-type (black), GOT1-null (blue) and
rescued GOT1-null (gray) Jurkat cells in the absence and presence (10 mM) of aspartate after treatment with the indicated phenformin concentrations for 5 days
(mean ± SD, n = 3, **p < 0.05) (top). Representative bright-field micrographs of indicated cells after a 5-day phenformin treatment in the absence or presence of
aspartate (bottom).
(E) Expression of a glutamate-aspartate transporter (SLC1A3) rescues the phenformin-induced death of GOT1-null cells cultured in standard RPMI media, which
contains only 150 mM aspartate. Fold change in cell number (log2) of GOT1-null (blue) and SLC1A3-overexpressing GOT1-null (gray) Jurkat cells in RPMI (150 mM
aspartate) after a 5-day treatment with 10 mM phenformin (mean ± SD, n = 3, **p < 0.05).
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Figure 4. Metabolic Routes of Aspartate Synthesis in Cells with ETC
Inhibition
(A) Schematic depicting oxidative and reductive glutamine metabolism path-
ways. Green and blue arrows indicate oxidative and reductive arms of the TCA
cycle, respectively. Filled circles represent 13C atoms derived from [U-13C]-L-
glutamine.
(B) Upon ETC inhibition, aspartate is mainly synthesized by reductive meta-
bolism of glutamine in a GOT1-dependent manner. Mass isotopomer analysis
of aspartate in wild-type and GOT1-null Jurkat cells cultured for 7 hr with
[U-13C]-L-glutamine in the presence or absence of phenformin (10 mM).
Aspartate pool sizes (top) and fraction of labeled aspartate derived from
labeled glutamine (bottom) for each sample are indicated in separate graphs
(mean ± SD, for n = 3, **p < 0.05). OAA, oxaloacetate.dropped, and what remained came primarily from reductive
glutamine metabolism with almost no contribution from the
oxidative pathway (Figure 4B). Reductive formation of aspartate
completely depends on GOT1 activity, as in phenformin-treated
GOT1-null cells there was almost no generation of aspartate or
aspartate-derived nucleotide precursors from labeled glutamine
(Figure 4B, Figure S4C). These results indicate that upon ETC
inhibition cells use the reductive carboxylation of glutamine to
fuel compensatory aspartate synthesis via a GOT1-requiring
pathway.
Pyruvate Stimulates Aspartate Synthesis in a
GOT1-Dependent Fashion
It has long been appreciated that human cells with ETC
dysfunction can proliferate when cultured in media containing
supra-physiological concentrations of pyruvate (Harris, 1980).Remarkably, pyruvate even enables the proliferation of cells
that have deleterious mutations in their mitochondrial DNA or
lack it altogether (143B r0 cells) (King and Attardi, 1989). Pyru-
vate has been hypothesized to act as a biosynthetic substrate
or to maintain the cellular redox state in cells with ETC dysfunc-
tion via reduction by lactate dehydrogenase, which helps
regenerate the NAD+ that is lost upon ETC inhibition (Harris,
1980; Wilkins et al., 2014). The NAD+ made through pyruvate
reduction should facilitate glycolytic flux and thus ATP produc-
tion in cells lacking ETC function, but the key metabolic conse-
quence of pyruvate addition that allows such cells to proliferate
is unclear.
As both pyruvate and aspartate supplementation enables
the proliferation of cells with ETC dysfunction, we explored a
possible link between the two by culturing wild-type and
GOT1-null cells in the presence or absence of pyruvate and
treating them with ETC inhibitors. Consistent with previous re-
ports (Harris, 1980), pyruvate almost completely blocked the
anti-proliferative effects of several ETC inhibitors (phenformin,
piericidin, and antimycin) on wild-type Jurkat cells (Figure 5A).
In contrast, pyruvate had no beneficial effect on the GOT1-null
cells (Figure 5A), suggesting that the pyruvate-mediated rescue
requires aspartate synthesis via GOT1. Indeed, pyruvate
restored aspartate levels to normal in phenformin-treated wild-
type cells, but had no effect on aspartate in phenformin-treated
GOT1-null cells (Figure 5B). Collectively, these data indicate that
a key mechanism through which pyruvate restores the prolifera-
tion of cells with ETC inhibition is to promote GOT1-catalyzed
aspartate synthesis (Figure 5C).
Metabolic Path of Pyruvate-Induced Aspartate
Synthesis
To understand how pyruvate stimulates aspartate synthesis in
cells with ETC inhibition, we considered two pathways through
which pyruvate might contribute to the aspartate pool. (1) One
possibility is that pyruvate carboxylase (PC) directly carboxyl-
ates pyruvate into oxaloacetate, which GOT1 then uses to
generate aspartate. However, we quickly ruled out this pathway
as in PC-null Jurkat cell lines pyruvate still prevented the anti-
proliferative effects of ETC inhibitors (Figure S5A). (2) As
described earlier, pyruvate can promote the regeneration of
NAD+ in the cytosol. Given this, we hypothesized that NAD+
might activate the cytosolic malate dehydrogenase (MDH1) to
generate oxaloacetate that then drives aspartate synthesis by
GOT1. To investigate this possibility, we generated MDH1-
null Jurkat cells (MDH1_KO1 and MDH1_KO2) (Figure 6A). In
the absence of ETC inhibitors, these cells had similar levels
of aspartate as GOT1-null cells, consistent with MDH1 normally
consuming the oxaloacetate generated by GOT1 from aspar-
tate (Figure 6B). Upon phenformin treatment, aspartate in the
MDH1-null cells dropped to the same level as it did in wild-
type cells (Figure 6B). Pyruvate, however, had no effect on
the MDH1-null cells: in cells treated with ETC inhibitors it did
not stimulate aspartate synthesis or rescue their proliferation
(Figures 6A and 6B). Importantly, aspartate supplementation
or expression in the null cells of an sgRNA-resistant human
MDH1 cDNA reversed this proliferation defect (Figures 6A
and 6B, Figure S5C). Our findings suggest a model in whichCell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc. 545
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Figure 5. In Cells with ETC Inhibition Pyru-
vate Stimulates Aspartate Synthesis in a
GOT1-Dependent Fashion
(A) Pyruvate cannot rescue death of GOT1-null
cells induced by ETC inhibitors. Fold change in cell
number (log2) of wild-type (black) and GOT1-null
(blue) Jurkat cells in the presence or absence of
pyruvate (1 mM) after treatment with phenformin
(10 mM), antimycin (1 mM) and piericidin (1 mM) for
5 days (mean ± SD, n = 3, **p < 0.05).
(B) In cells with ETC inhibition pyruvate addition
increases cellular aspartate levels in a GOT1-
dependent manner. Relative aspartate levels were
measured in wild-type (black), GOT1-null (blue),
and rescued GOT1-null (gray) Jurkat cells in the
presence (1 mM) or absence of pyruvate after a
24 hr phenformin (10 mM) treatment using LC-MS/
MS (mean ± SD, for n = 3, **p < 0.05). All mea-
surements are relative to untreated wild-type
Jurkat cells.
(C) Proposed mechanism of pyruvate-mediated
rescue of cell proliferation upon ETC inhibition.pyruvate-induced NAD+ activates MDH1 to produce oxaloace-
tate from malate and drive aspartate synthesis via GOT1. In
addition, the reductive pathway to oxaloacetate synthesis that
operates in the absence of pyruvate (Figure 6C) is still opera-
tional, so in the presence of pyruvate there are likely multiple
ways of fueling GOT1 for aspartate synthesis (Figure 6C). Sup-
porting the idea that redox balance is upstream of aspartate
synthesis, aspartate addition, unlike that of pyruvate, did not
restore the NAD/NADH ratio in cells with ETC inhibition
(Figure S5B).
Although under normal conditions both GOT1- and MDH1-
null cells have high aspartate levels, they behave strikingly
differently upon ETC inhibition: aspartate levels become
almost undetectable in GOT1-null cells and the cells die,
while in MDH1-null cells aspartate and proliferation drop to
the same extent as in wild-type cells (Figure 6D). This major
difference in aspartate levels upon ETC inhibition is a conse-
quence of the MDH1-null (and also wild-type) cells being
able to generate some aspartate even in the absence of pyru-
vate through the reductive carboxylation pathway described
earlier while the GOT1-null cells cannot (Figure 4). In other
words, in the absence of ETC function, the loss of GOT1 elim-
inates all routes to aspartate synthesis while the reductive
carboxylation path is still available in the MDH1-null and
wild-type cells.
This conclusion also provides a rationale for why MDH1 did
not score like GOT1 in our screen, which was performed in
RPMI, a pyruvate-free medium (Figure 1B). In the absence of
pyruvate and when treated with ETC inhibitors, MDH1-null and
wild-type cells have comparable aspartate levels and proliferate
equally poorly (Figures 6A and 6B). Interestingly, aspartate levels
in wild-type, GOT1-null, and MDH1-null cells treated with ETC
inhibitors are a good predictor of whether the cells proliferate,
arrest, or die (Figure 6D).546 Cell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc.Aspartate Supplementation Enables the Proliferation of
Cybrids with Patient-Derived mtDNA Mutations Even in
the Absence of Pyruvate
Transmitochondrial cytoplasmic hybrid cells (cybrids) are
commonly used to study the mechanisms through which muta-
tions in mitochondrial DNA (mtDNA) impair cellular function
(Schon et al., 2012). These cells harbor patient-derived mito-
chondrial genomes with pathogenic mutations, and, like cells
treated with ETC inhibitors, require pyruvate to proliferate in
culture (King and Attardi, 1989, 1996). Complex III deficient
cybrid cells also require the addition of uridine to the media as
complex III is needed for its synthesis (Lo¨ffler et al., 1997). To
expand upon our work with pharmacological inhibition of the
ETC, we asked if aspartate supplementation rescues the prolifer-
ation of cells with genetic ETC defects. We used two patient-
derived cybrid cells, the first with a homoplasmic microdeletion
in the cytochrome b subunit of complex III (CYTB) associated
with a form of parkinsonism and encephalopathy (De Coo
et al., 1999; Rana et al., 2000), and the second with a homoplas-
mic point mutation in the mitochondrially encoded tRNA lysine
(MT-TK) associated with myoclonic epilepsy with ragged red fi-
bers (MERRF) (Wallace et al., 1988). To characterize the meta-
bolic needs of these cybrids, as well as cells lacking mtDNA
(143B r0), we cultured them in media with or without pyruvate
or aspartate. In agreement with previous reports, the ETC-defi-
cient cybrids and r0 cells proliferated in media supplemented
with pyruvate (Figure 7A). Consistent with the data obtained
with pharmacological inhibitors, pyruvate stimulated aspartate
synthesis in the ETC-defective cells (Figure 7B) and aspartate
on its own enabled their proliferation (Figure 7A). The pyruvate-
mediated rescue requires GOT1 as knocking it out in the ETC-
defective cybrids severely impaired their proliferation (Figure 7C).
Importantly, aspartate supplementation bypassed the need for
GOT1 (Figure 7C).
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Figure 6. Cells with ETC Inhibition Require
MDH1 for Pyruvate to Stimulate Aspartate
Synthesis and Enable Proliferation
(A) Pyruvate does not rescue the proliferation of
phenformin-treated MDH1-null cells. Immunoblot
analysis of wild-type and MDH1-null Jurkat cells
along with counterparts expressing an sgRNA-
resistant MDH1 cDNA (left). mTOR and Raptor
were used as loading controls. Relative fold
change in cell number of wild-type (black), MDH1-
null (light blue), and rescued MDH1-null (gray)
Jurkat cells after a 5-day treatment with phenfor-
min (10 mM), piericidin (1 mM), and antimycin (1 mM)
in the presence or absence of pyruvate (1 mM)
(mean ± SD, n = 3, **p < 0.05) (right).
(B) The pyruvate-induced increase in aspartate
synthesis depends on MDH1. Relative aspartate
levels were determined in wild-type (black), GOT1-
null (blue), andMDH1-null (light blue) Jurkat cells in
the presence or absence of pyruvate (1 mM) after a
24 hr phenformin (10 mM) treatment (mean ± SD,
for n = 3, **p < 0.05). All measurements are relative
to untreated wild-type Jurkat cells.
(C) Metabolic routes for pyruvate-induced aspar-
tate synthesis under ETC inhibition.
Pyruvate, through the lactate dehydrogenases,
regenerates NAD+ in the cytoplasm. This NAD+
can activate the cytoplasmic malate dehydroge-
nase to provide OAA from malate and drive
aspartate synthesis via GOT1. Alternatively,
another source for OAA is through ATP-citrate
lyase, which catalyzes the conversion of citrate
and CoA into acetyl-CoA and OAA in the cytosol.
Under ETC inhibition, the latter reaction is likely
less dependent on NAD+ and can work even in the absence of pyruvate supplementation. Note that both pathways are dependent on GOT1.
(D) Aspartate levels correlate with cellular health upon ETC inhibition. ETC inhibition leads to a decrease in aspartate levels and inhibits cell proliferation in
wild-type cells. The residual aspartate generated by GOT1 is sufficient to maintain viability, as GOT1 loss results in cell death and corresponds to an
almost complete depletion of aspartate. Pyruvate addition rescues aspartate levels and proliferation under ETC inhibition in a GOT1- and MDH1-dependent
fashion.To test the sufficiency of aspartate in enabling the prolifera-
tion of cells with genetic ETC defects, we stably expressed
the glutamate-aspartate SLC1A3 transporter in the CYTB cy-
brids (Figure 7D). Strikingly, SLC1A3 expression was sufficient
to enable the cybrids to proliferate in standard RPMI media,
which has a low aspartate concentration (150 mM) and no
pyruvate (Figure 7D). To rule out the possibility that SLC1A3
enables proliferation by transporting a molecule other than
aspartate, we cultured the cells in aspartate-free RPMI. Now,
the SLC1A3-expressing CYTB cybrids failed to proliferate in
the absence of pyruvate. Thus, we conclude that aspartate is
sufficient to enable the proliferation of cells with a genetic
ETC defect.
CONCLUSIONS
Our work suggests that an essential role of the electron transport
chain (ETC) in cell proliferation is to enable the biosynthesis of
aspartate. Even though ETC inhibition impacts many processes,
the supplementation of media with aspartate alone, or the
expression in cells of an aspartate transporter, is sufficient to
allow ETC-defective cells to proliferate in culture. We also
provide an explanation for the classic finding of King and Attardi(King and Attardi, 1989, 1996) that respiration-defective mam-
malian cells require supra-physiological levels of pyruvate to
proliferate. We find that pyruvate, likely by normalizing
redox levels (Sullivan, et. al., 2015, this issue of Cell), promotes
aspartate synthesis to rescue the proliferation of cells with
severe ETC defects. It is important to note that although severe
ETC inhibition has anti-proliferative effects, the mild ETC
inhibition observed in cancer cells having heteroplasmic mtDNA
mutations might have beneficial effects on tumorigenesis, likely
not by affecting aspartate synthesis, but perhaps by increasing
ROS levels (Ishikawa et al., 2008; Kulmacz, 1989; Petros et al.,
2005).
As blood aspartate concentrations in children and adults are
very low (0–15 mM) (Newgard et al., 2009; Wuu et al., 1988), it
is unlikely that in vivo cells with ETC inhibition can take up
sufficient aspartate to compensate for the decrease in its
synthesis. If future work shows that defective aspartate synthe-
sis contributes to the pathophysiology of diseases characterized
by ETC dysfunction, it will be necessary to consider therapies
that increase cellular aspartate levels in vivo. One can imagine
several strategies for accomplishing this, including delivery of
cell-permeable aspartate-releasing pro-drugs or small mole-
cules that indirectly boost aspartate by increasing pyruvate orCell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc. 547
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Figure 7. Aspartate Supplementation En-
ables the Proliferation of Patient-Derived
Cybrids with mtDNA Mutations and Re-
places the Need for Pyruvate
(A) Aspartate can replace pyruvate in enabling the
proliferation of patient-derived mtDNA mutant
cybrids and 143B r0 cells devoid of mtDNA. Cell
line models of ETC dysfunction were cultured in
RPMI (supplemented with 50 mg/ml uridine to
bypass the need for complex III in uridine synthe-
sis) with pyruvate (1 mM) or aspartate (10 mM) for
6 days. Relative cell number was determined by
normalizing to the pyruvate-supplemented condi-
tion. Representative bright-field micrographs of
MERRF, CYTB, and 143B r0 cells after 6 days
in indicated conditions (right) (mean ± SD, n = 3,
**p < 0.05).
(B) Pyruvate stimulates aspartate biosynthesis in
cybrid cells with ETC dysfunction.
Mass isotopomer analysis of aspartate in wild-
type, phenformin-treated wild-type, and ETC-
defective cybrid cells cultured for 7 hr with [U-13C]-
L-glutamine in the presence or absence of
pyruvate (1 mM). The fraction of labeled aspartate
from [U-13C]-L-glutamine is indicated (mean ± SD,
for n = 3, **p < 0.05). OAA, oxaloacetate.
(C) Pyruvate supplementation enables the prolif-
eration of patient-derived cybrid cells in a
GOT1-dependent fashion that can be bypassed
by aspartate. Immunoblot analysis of wild-type,
MERRF, and CYTB cybrid cells expressing
sgControl and sgGOT1 (top). Raptor was used as
a loading control. Cell line models of ETC
dysfunction expressing sgControl or sgGOT1were
cultured in RPMI (supplemented with uridine
(50 mg/ml) and pyruvate (1 mM)) with or without
aspartate (10 mM) for 6 days (bottom). Relative
cell number was determined by normalizing to
sgControl expressing cell line (mean ± SD, for
n = 3, **p < 0.05).
(D) SLC1A3 overexpression enables CYTB cells
to proliferate in standard RPMI media without
pyruvate addition. Fold changes in cell number
over time of 143B wild-type, CYTB cybrid cells,
and their SLC1A3-expressing counterparts when
cultured in RPMI media lacking aspartate and
pyruvate (blue), or supplemented with aspartate
(150 mM) (black) or pyruvate (1 mM) (gray) (mean ±
SD, n = 3).the NAD+/NADH ratio. Two case reports showing that pyruvate
treatment of patients with mitochondrial disease has some clin-
ical benefit (Fujii et al., 2014; Saito et al., 2012) supports the
notion that the pyruvate-aspartate axis may be of therapeutic in-
terest. Efforts to explore this possibility are warranted given that
current therapies for these diseases are of limited efficacy
(Pfeffer et al., 2012).EXPERIMENTAL PROCEDURES
CRISPR-Based Screen
The metabolism-focused sgRNA library was designed and performed as
previously described (Wang et al., 2014). Oligonucleotides for sgRNAs548 Cell 162, 540–551, July 30, 2015 ª2015 Elsevier Inc.were synthesized by CustomArray Inc. and amplified by PCR (Wang et al.,
2014). Gene scores of all the metabolic genes in the screen can be found
in Table S1.Proliferation Assays
Indicated cell lines were cultured in replicates of three in 96-well plates at
2–3,000 cells per well in 200 ml RPMI base media under the conditions
described in each experiment, and a separate group of 3 wells was also
plated for each cell line with no treatment for an initial time point. After
5 hr (untreated cells for initial time point) or after 5 days (with varying
treatment conditions), 40 ml of Cell Titer Glo reagent (Promega) was added
to each well, mixed briefly, and the luminescence read on a Luminometer
(Molecular Devices). For each well, the fold change in luminescence relative
to the initial luminescence was measured and reported in a log2 scale. For
Figure 6, relative fold change in luminescence relative to initial was
calculated.
Cell Counting Assays
Cybrids or 143B r0 cells were plated in triplicate in 12 well plates at
5,000–20,000 cells per well in 1.5 ml as described in each experiment.
After 6 days, the entire contents of the well was trypsinized and counted
using a Beckman Z2 Coulter Counter with a size selection setting of 8–30 mm.
Generation of Knockout and cDNA Overexpression Cell Lines
sgRNAs (oligonucleotide sequences are indicated above) were cloned into
lentiCRISPR-v1 linearized with BsmBI by Gibson Assembly (NEB). sgRNA
expressing vector along with lentiviral packaging vectors Delta-VPR and
CMV VSV-G were transfected into HEK293T cells using the XTremeGene 9
transfection reagent (Roche). Similarly, for overexpression cell lines, cDNA
vectors along with retroviral packaging vectors gag-pol and CMV VSV-G
were transfected into HEK293T cells. Media was changed 24 hr after
transfection. The virus-containing supernatant was collected 48 and 72 hr af-
ter transfection and passed through a 0.45 mm filter to eliminate cells. Target
cells in 6-well tissue culture plates were infected in media containing 8 mg/ml
of polybrene and a spin infection was performed by centrifugation
at 2,200 rpm for 1 hr. Post-infection, virus was removed and cells were
selected with puromycin or blasticidin. For knockout cells, after selection,
cells were single-cell sorted with a flow cytometer into the wells of a
96-well plate containing 200 ml of RPMI supplemented with 20% FBS.
Cells were grown for 2 weeks, and the resultant colonies were trypsinized
and expanded. Clones were validated for loss of the relevant protein via
immunoblotting.
Metabolite Profiling and Isotope Tracing
LC/MS analyses were conducted on a QExactive benchtop orbitrap mass
spectrometer equipped with an Ion Max source and a HESI II probe, which
was coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher Scienti-
fic, San Jose, CA). External mass calibration was performed using the stan-
dard calibration mixture every 7 days.
For metabolite profiling experiments, Jurkat cells (2 million per sample)
were incubated with 10 mM phenformin for 24 hr. Similarly, for glutamine
tracing experiments, Jurkat cells (2 million per sample) were incubated
with 10 mM phenformin for 18 hr; the cells were spun down and media
was replaced with RPMI supplemented with 1 mM [U-13C]-L-glutamine for
7 hr. Polar metabolites were extracted using 1 ml of ice-cold 80% methanol
with 10 ng/ml valine-d8 as an internal standard. After a 10 min vortex
and centrifugation for 10 min at 4C at 10,000 g, samples were dried under
nitrogen gas. Dried samples were stored at 80C and then resuspended in
100 ml water; 1 ml of each sample was injected onto a ZIC-pHILIC 2.1 3
150 mm (5 mm particle size) column (EMD Millipore). Buffer A was 20 mM
ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetoni-
trile. The chromatographic gradient was run at a flow rate of 0.150 ml/min
as follows: 0–20 min.: linear gradient from 80% to 20% B; 20–20.5 min.:
linear gradient from 20% to 80% B; 20.5–28 min.: hold at 80% B. The
mass spectrometer was operated in full-scan, polarity switching mode
with the spray voltage set to 3.0 kV, the heated capillary held at 275C,
and the HESI probe held at 350C. The sheath gas flow was set to 40 units,
the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to
1 unit. The MS data acquisition was performed in a range of 70–1000 m/z,
with the resolution set at 70,000, the AGC target at 106, and the maximum
injection time at 80 msec. Relative quantitation of polar metabolites was
performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using
a 5 ppm mass tolerance and referencing an in-house library of chemical
standards.
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